Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid.
about
Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicityN-alkylprotoporphyrin formation and hepatic porphyria in dogs after administration of a new antiepileptic drug candidate: mechanism and species specificityQuantitative determination of valproic acid and 14 metabolites in serum and urine by gas chromatography/mass spectrometry.Valproic acid pathway: pharmacokinetics and pharmacodynamics.Identifying genomic and developmental causes of adverse drug reactions in children.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Role of metabolism in drug-induced idiosyncratic hepatotoxicity.Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.Mechanisms of drug toxicity and relevance to pharmaceutical development.Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury.Study of valproic acid-induced endogenous and exogenous metabolite alterations using LC-MS-based metabolomics.Abnormal alterations in the metabolic patterns of patients on valproate therapy.Identification of novel metabolites of pioglitazone in rat and dog.Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype.
P2860
Q28324498-5D34AC52-8AFE-4D93-9903-E490CB91C899Q28834645-FAFB1B7F-D993-49D8-AE19-BBAE5715824EQ33218447-71BC27C4-5AAD-4542-941F-2F74D6D3F4B0Q34327652-EFB6E385-1AA1-42F8-AF07-657D35903B41Q34603032-33687DEA-190F-42B0-A78B-3D22D1782B88Q36061821-D81C2927-C691-416A-9B5E-BF8497279D40Q36179528-525EE74F-26EA-47E3-89E3-ED7C175418D0Q36662875-C2A6A25A-032A-4C5A-A411-41EF31A845B6Q36835826-C693BBA6-A315-4D1E-814B-3147A73B314EQ37803316-A20C54FA-8DF2-41A8-A27D-3B9EA8EA80AFQ40817414-F1603C21-34D2-4B0A-A80E-7F929A6B014FQ42806991-3E3B7151-1841-440A-8252-23B1CF06E01DQ44090049-13C4A40A-95F2-45E4-9380-072A620D2276Q44440351-1EBA9330-E9F2-4D04-A792-3AFF69188ED5Q46861134-087841A3-894E-48B1-B1EE-1E3388D059F2
P2860
Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Metabolic activation of valpro ...... , 2-n-propyl-4-pentenoic acid.
@en
Metabolic activation of valpro ...... , 2-n-propyl-4-pentenoic acid.
@nl
type
label
Metabolic activation of valpro ...... , 2-n-propyl-4-pentenoic acid.
@en
Metabolic activation of valpro ...... , 2-n-propyl-4-pentenoic acid.
@nl
prefLabel
Metabolic activation of valpro ...... , 2-n-propyl-4-pentenoic acid.
@en
Metabolic activation of valpro ...... , 2-n-propyl-4-pentenoic acid.
@nl
P356
P1476
Metabolic activation of valpro ...... , 2-n-propyl-4-pentenoic acid.
@en
P2093
T A Baillie
P304
P356
10.1021/TX00004A001
P577
1988-07-01T00:00:00Z